Biomarkers

Genialis Expands Support for Clinical Biomarker Discovery Platform

Retrieved on: 
Thursday, June 10, 2021
Software, Research, Other Health, Pharmaceutical, Data management, Oncology, Technology, Genetics, Clinical trials, Science, Biotechnology, Health, Other Science, Branches of biology, Biology, Life sciences, Biomarkers, Clinical research, Medical statistics, Biotechnology, Medical signs, Clinical trial, Clinical endpoint

Genialis' AI-enabled biomarker discovery platform serves as an end-to-end solution that de-risks clinical development, but also drives early discovery and supports translational investigations.

Key Points: 
  • Genialis' AI-enabled biomarker discovery platform serves as an end-to-end solution that de-risks clinical development, but also drives early discovery and supports translational investigations.
  • Genialis platform helps address the problem of high clinical trial failure rates and long and expensive R&D slogs.
  • Now, we are most excited about using our biomarker platform to help bridge from successful early discovery to translational evidence to improved clinical outcomes.
  • To bolster its support of clinical biomarker collaborations, Genialis has added two domain experts to its team of applied scientists and alliance managers.

DGAP-News: SphingoTec Expands Management Team and Appoints new CFO

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Biology, Biomarkers, Life sciences, Biotechnology, Chemical pathology, Medical signs, Cell biology, Personalized medicine

Dr. Angelo Moesslang was named CFO and Managing Director of SphingoTec.

Key Points: 
  • Dr. Angelo Moesslang was named CFO and Managing Director of SphingoTec.
  • Hennigsdorf/Berlin, Germany, June 10, 2021 - Diagnostics company SphingoTec GmbH ("SphingoTec") announces the appointment of Dr. Angelo Moesslang as new chief financial officer (CFO) and managing director.
  • SphingoTec develops and markets innovative in vitro diagnostic solutions for novel biomarkers that support personalized medicine in critical care conditions.
  • Sphingotec is a fully integrated diagnostics company: the innovative biomarkers are commercially available on the proprietary point of care platform Nexus IB10.

Next Generation Biomarkers. A Journey of Multiomic Translational Science from Discovery to Companion Diagnostics, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Biology, Biomarkers, Medicine, Biomarker discovery, Companion diagnostic, Medical device, Data mining

At the same time, our data mining and AI capabilities have opened massive opportunities from biomarker discovery to companion diagnostic commercialization.

Key Points: 
  • At the same time, our data mining and AI capabilities have opened massive opportunities from biomarker discovery to companion diagnostic commercialization.
  • On the other hand, the ever-increasing amount of data and complexity presents new challenges in biomarker development: from Discovery, Validation and Regulatory Approval.
  • A Journey of Multiomic Translational Science from Discovery to Companion Diagnostics.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

Hummingbird Bioscience and Novogene enter into strategic partnership to expand precision medicine testing for individuals with NRG1-fusion driven cancers in China

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Biology, Biomarkers, Life sciences, Cancer research

The partnership will focus on validation and expansion of clinical-grade testing for NRG1 fusions in key patient populations with selected solid tumors.

Key Points: 
  • The partnership will focus on validation and expansion of clinical-grade testing for NRG1 fusions in key patient populations with selected solid tumors.
  • The collaboration with Novogene will allow us to create testing options for patients with NRG1-fusions, as well as providing greater awareness as we expand our clinical program into China," said Piers Ingram, Chief Executive Officer and co-founder of Hummingbird Bioscience.
  • "We look forward to building on our collaboration with Novogene to expand diagnostic options beyond NRG1-fusions into other molecular biomarkers."
  • Cancer Research UK has partnered with Hummingbird Bioscience to advance this novel drug candidate into clinical trials for the treatment of HER3-driven cancers.

LARVOL Launches Platform to Curate Historical and Active Immuno-Oncology Clinical Trial Data in a Digital Dashboard

Retrieved on: 
Tuesday, June 8, 2021
Research, Technology, Clinical trials, Software, Biotechnology, Pharmaceutical, Health, Data management, Science, Oncology, Biomarkers, Branches of biology, Biology, Medicine, Cancer biomarker, Clinical trial

This SaaS platform allows cancer researchers and drug developers to search and analyze data across all clinical trials within a specific cancer type.

Key Points: 
  • This SaaS platform allows cancer researchers and drug developers to search and analyze data across all clinical trials within a specific cancer type.
  • Faster Curation: LARVOLs team of experts manually review new trial data with speed and precision, posting results and exhibits in less than 24 hours so data is available in hours, not days.
  • Easier Searching: Detailed meta-tags make it easy to search, filter, and browse trial data by tumor type, drug, phase, endpoint, or even medical conference.
  • Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases.

Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Biology, Biomarkers, Life sciences, Biotechnology, Chemical pathology, Medical signs, Cell biology, Oncology

Data presented in this study complemented initial findings presented at the 2020 ASCO annual meeting ( abstract 3630 ).

Key Points: 
  • Data presented in this study complemented initial findings presented at the 2020 ASCO annual meeting ( abstract 3630 ).
  • Notably, the current study introduced data on clinical outcome predictions based on the results of the PARIS Test.
  • Study authors also found concordance between PARIS Test drug responses and known genomic biomarkers, such as KRASG12 mutation and MEK inhibitors.
  • Moreover, the strong predictive value of the PARIS Test provides treating oncologists with a tool to identify personalized therapeutic options to a given patients cancer.

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Medicine, Biology, Biotechnology, Biomarkers, Chemical pathology, Blarcamesine, Precision medicine

"Given ANAVEX2-73s convenient oral route of administration we believe it has the potential to deliver broad clinical utility."

Key Points: 
  • "Given ANAVEX2-73s convenient oral route of administration we believe it has the potential to deliver broad clinical utility."
  • Anavex Life Sciences product portfolio includes small drug molecule lead candidate ANAVEX2-73 for the treatment of Alzheimers disease, Parkinsons disease and Rett syndrome.
  • The Phase 2b/3 study is expected to enroll approximately 450 patients, randomized 1:1:1 to two different ANAVEX2-73 doses or placebo.
  • The ANAVEX2-73 Phase 2b/3 study design includes genomic precision medicine biomarkers identified in the previous ANAVEX2-73 Phase 2a study (ANAVEX2-73-002, NCT02244541).

Global Biomarker Partnering: Updated Deal Trends, Players and Financials 2010-2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Health, Biotechnology, Biomarkers, Biology, Life sciences, Project DEAL

The Global Biomarker Partnering Terms and Agreements 2010-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Key Points: 
  • The Global Biomarker Partnering Terms and Agreements 2010-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
  • The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.
  • Global Biomarker Partnering Terms and Agreements 2010-2021: Deal trends, players and financials provide the reader with the following key benefits:
    Insight into the terms included in a biomarker agreement, together with real-world clause examples
    Global Biomarker Partnering Terms and Agreements 2010-2021: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.
  • Biomarker Partnering Terms and Agreements includes:
    In Global Biomarker Partnering Terms and Agreements 2010-2021: Deal trends, players and financials, the available contracts are listed by:
    Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research

Retrieved on: 
Friday, June 4, 2021
Oncology, Health, Other Health, Research, Science, Biotechnology, Biomarkers, Biology, Branches of biology, Medicine, Imaging biomarker, Cancer biomarker, The US Oncology Network, US Oncology Research, Ontada, THE US ONCOLOGY NETWORK, US ONCOLOGY RESEARCH, ONTADA

The findings provide a close-up look at current biomarker testing rates and turnaround times for patients with mNSCLC treated in community practices within The Network.

Key Points: 
  • The findings provide a close-up look at current biomarker testing rates and turnaround times for patients with mNSCLC treated in community practices within The Network.
  • Unfortunately, barriers exist that prevent the necessary comprehensive biomarker testing that enables the use of these treatments.
  • The MYLUNG Consortium is a collaborative and innovative research study comprised of three protocols over a five-year period.
  • Ontada is an oncology data, research and technology business dedicated to improving the lives of cancer patients.

Strata Oncology Presents Data at ASCO 2021 Showing Comprehensive Genomic and Transcriptomic Profiling Predicts Pan-Tumor Benefit of Pembrolizumab

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Clinical medicine, Biology, Biomarkers, American Society of Clinical Oncology, Pembrolizumab, Oncology, Precision medicine

The data were shared during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021.

Key Points: 
  • The data were shared during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021.
  • The multivariate signature, developed from the Strata clinical-molecular database and real-world data, also predicted pembrolizumab benefit relative to chemotherapy across solid tumors.
  • Strata's multivariate biomarker, derived from our genomic and transcriptomic profiling assay, may expand the pan-tumor treatable population beyond current biomarkers."
  • Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer.